The biotech sought to bear this mechanism out in STRIDES, a mid-stage, randomized, double-blinded and placebo-controlled trial that evaluated the efficacy and basic safety of azelaprag—with and with out Eli Lilly’s blockbuster incretin remedy tirzepatide—in a lot more than two hund